The purpose of this study is to compare how the body absorbs different versions of Lenvatinib 10 mg capsules, including two test products and one reference product, when taken both with and without food. The study will measure how much of the medication enters the bloodstream and how long it stays in the body. This is done by looking at the highest level of medication in the blood, when this highest level occurs, and the total amount of medication in the blood over time. The study will also evaluate safety by monitoring any unwanted effects, heart activity through electrical recordings, vital signs like blood pressure and heart rate, and laboratory test results.

The study involves healthy volunteers who will receive single doses of the medication in different treatment periods. Participants will take each version of the capsule at different times, with breaks between treatments, to allow comparison of how each version works in the body. The study design allows each person to receive all three treatments in a specific order, with some participants taking the medication without food and others taking it with food. Blood samples will be collected to measure the levels of medication, and participants will be monitored throughout the study for any changes in their health.

The purpose of the study is to determine the best time to take images using the [18F]Tetrafluoroborate PET/CT and to see how well it can detect cancer that has spread to nearby lymph nodes before surgery. It will also assess how useful this imaging method is in predicting how patients with persistent or returning thyroid cancer will respond to a common treatment called radioiodine therapy. The study will involve patients who have been newly diagnosed with differentiated thyroid cancer and those who are undergoing treatment.

Throughout the study, participants will receive the [18F]Tetrafluoroborate injection and undergo PET/CT scans. These scans will help doctors see how the cancer is behaving and whether it has spread. The study will also look at how the substance is absorbed in normal thyroid tissue, the primary tumor, and any areas where the cancer has spread. This information could help improve the way thyroid cancer is diagnosed and treated in the future.

The purpose of this study is to explore how pembrolizumab works as a treatment before surgery in patients with high-risk thyroid cancer. Participants in the study will receive pembrolizumab to see how it affects their cancer and immune system. The study will involve regular monitoring and assessments to understand the medication’s impact on the cancer and the body’s immune response.

Throughout the study, researchers will collect and analyze samples to learn more about how pembrolizumab influences the immune system and its ability to target cancer cells. This research aims to provide insights into the potential benefits of using pembrolizumab as a treatment option for thyroid cancer, particularly in cases where the cancer is considered high-risk. The study is expected to continue until 2026, with the goal of improving treatment strategies for thyroid cancer patients.

The purpose of the study is to evaluate how metformin affects certain fertility indicators in women, such as hormone levels and the number of small follicles in the ovaries, which are checked using an ultrasound. The study will also look at how metformin might influence other factors like oxidative stress, which is an imbalance between free radicals and antioxidants in the body, and apoptosis, which is the process of programmed cell death. Additionally, the study will assess the quality of life of participants using a specific questionnaire designed for thyroid cancer patients.

Participants will be involved in the study over a period of time, attending several visits where these various factors will be measured and compared. The study will help to understand if metformin can improve fertility outcomes for women who have undergone treatment for papillary thyroid cancer, as well as its overall safety and tolerability in this group of patients.

Participants in the study will take Cabozantinib tablets by mouth. The study will last for a period of time, during which participants will have regular check-ups and tests to monitor their health and the effects of the medication. The study will also collect blood samples to look for specific markers that might help predict the effectiveness of the treatment. These markers are like signals in the blood that can give doctors clues about how the cancer is responding to the medication.

The study aims to gather information on how well Cabozantinib controls the disease, how long any positive effects last, and the overall survival of participants. It will also look at the safety of the medication by tracking any side effects that occur. The information collected will help doctors understand more about the potential benefits and risks of using Cabozantinib for treating this specific type of thyroid cancer.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

Participants in the study will be randomly assigned to one of two groups. One group will receive radioiodine treatment based on a routine schedule, while the other group will have their treatment decisions guided by tests done after surgery. These tests include measuring a protein in the blood called thyroglobulin (Tg) and using a special imaging test called diagnostic RAI scintigraphy. The study will follow participants for several years to see how well each strategy works in treating the cancer.

The trial aims to assess the response to treatment at different time points, such as one, three, and five years after starting the study. It will also look at the quality of life, anxiety, and any side effects related to the treatment. The study will help determine if the guided approach can provide similar or better outcomes compared to the standard method, potentially leading to more personalized treatment plans for patients with this type of thyroid cancer.

Participants in the study will receive an injection of the [18F]PSMA-11 solution, which is administered through a vein. After the injection, a PET scan will be performed to capture images of the cancerous areas. The study aims to observe how much of the imaging agent is taken up by the cancerous lesions, which can help in understanding the extent of the disease. This process will be repeated as needed to gather enough information for the study.

The study will last for a period during which all necessary scans and evaluations will be completed. The results will help determine the effectiveness of [18F]PSMA-11 in providing clear images of cancerous lesions in patients with advanced head and neck squamous cell carcinoma and thyroid carcinoma. This information could be valuable in improving the diagnosis and treatment planning for these types of cancer in the future.

The purpose of this research is to determine if personalizing the dose of radioactive iodine treatment based on detailed imaging studies can improve treatment effectiveness compared to using standard fixed doses. The study uses special imaging techniques called PET/CT scans with a different form of radioactive iodine (I-124) to help determine the optimal treatment dose for each patient.

During the study, participants may receive up to two treatments with radioactive iodine. The effectiveness of the treatment will be evaluated using various imaging techniques and blood tests to measure thyroid-specific markers. The study also aims to understand how genetic changes in the cancer and certain biological markers may affect how well the treatment works.

The study will test a medication called cabozantinib (also known as XL184) compared to placebo. The medication is given as film-coated tablets that are taken by mouth. The purpose is to determine if cabozantinib can slow down or stop cancer growth in patients whose disease has worsened after previous therapy.

During the study, participants will be randomly assigned to receive either cabozantinib tablets or placebo tablets. Neither the patients nor their doctors will know which treatment they are receiving. The treatment may continue for up to 51 months, with regular medical check-ups to monitor the patient’s condition. The study will track how long it takes for the cancer to progress and measure if the tumors shrink in response to treatment.